Abstract 86P
Background
Obesity rivals smoking as a leading modifiable risk factor for cancer mortality, accounting for up to 20% of adult cancer-related deaths. Diet is a crucial factor in obesity development and significantly influences cancer growth. Paradoxically, high BMI has been linked to improved immune checkpoint inhibitor (ICI) efficacy in various cancers, challenging the notion that obesity is universally detrimental in cancer contexts. To address this paradox, we devised a panel of 12 diets that mimic human dietary patterns in mouse models, observing vastly different rates of cancer growth and ICI response. Surprisingly, not all obesity-inducing diets were beneficial for ICI, prompting an investigation into the cause of these disparities. The microbiome's pivotal role in regulating cancer and therapy through its profound influence on the immune system is well-supported, with gut dysbiosis and antibiotic use increasing cancer risk and blunting ICI response in patients and fecal microbial transplant from ICI-responsive patients shown to enhance ICI therapy. We propose that the interplay between diet and systemic inflammatory responses to gut microbiota contributes to the variations in ICI response across obesity-inducing diet models.
Methods
To track the gut microbial composition changes in mice during the development of our 12-diet model, we collected stool samples and performed 16s rRNA sequencing. The analyses focused on four obesity-inducing diets: American, High Fat, Ketogenic and Mediterranean.
Results
Analysis unveiled differences in gut bacterial composition at the phylum level across all four obesity inducing diets. However, family-level changes were associated with ICI response in a diet-specific manner. To delve deeper into these findings, we conducted metagenomic sequencing, revealing specific species associated with ICI response in preliminary analyses.
Conclusions
These findings suggest that diet-induced gut microbial modifications, in the context of obesity, may influence ICI efficacy, and offers promising avenues for the development of new therapeutic approaches that utilize the microbiome to enhance cancer treatment outcomes.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Canadian Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
104P - Hypomethylated immune gene promoters as potential biomarkers in oral and oropharyngeal cancer
Presenter: Petra Anić
Session: Cocktail & Poster Display session
Resources:
Abstract
105P - Implementation of technical improvements in cfMeDIP-Seq library preparation
Presenter: Martina Dameri
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Clinical application of next-generation sequencing in metastatic colorectal cancer (mCRC): Experience from a comprehensive cancer centre
Presenter: David Lluís Garulo
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Unveiling mismatch repair deficiency (dMMR) and microsatellite-instability high (MSI-H) detection in cancer patients (pt) using a next-generation sequencing (NGS)-based molecular pre-screening program (MPP)
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
108P - Validation and implementation of a large NGS panel to test liquid biopsies from patients with suspected advanced non-small cell lung cancer (NSCLC) in an NHS genomic laboratory for the QuicDNA biomarker study
Presenter: Rachel Dodds
Session: Cocktail & Poster Display session
Resources:
Abstract
109P - A multiomic, single-cell measurable residual disease (scMRD) assay for phasing DNA mutations and surface immunophenotypes
Presenter: Simone Formisano
Session: Cocktail & Poster Display session
Resources:
Abstract
110P - Multicellular three-dimensional tumor spheroid of nasopharyngeal carcinoma
Presenter: Shiau Chuen Cheah
Session: Cocktail & Poster Display session
Resources:
Abstract
111P - Development of digital PCR for accurate measurement of HER2 amplification in 184 gastric cancer patients
Presenter: So Young Kang
Session: Cocktail & Poster Display session
Resources:
Abstract
112P - A novel methylation-sensitive assay for early detection of hepatocellular carcinoma to improve surveillance
Presenter: Jeong Sil Ha
Session: Cocktail & Poster Display session
Resources:
Abstract
113P - Evaluation of effects of tissue preservation methods on the proteome abundance through deep proteomics of breast cancer tissue
Presenter: Shashwati parihari
Session: Cocktail & Poster Display session
Resources:
Abstract